Iceland will likely participate in the European Union’s joint scheme to purchase and procure doses of Imvanex to use in cases of monkeypox infection, RÚV reports. At time of writing, no cases of monkeypox have been diagnosed in Iceland. After exploring its procurement options, the Ministry of Health says it monkeypox vaccinations would be administered to people who have been exposed to the virus and perhaps other select groups, but says that general vaccination against the virus is unnecessary.
According to the European Centre for Disease Prevention and Control, “there is a multi-country outbreak of monkeypox affecting the UK, EU/EEA states, and North America. This is the first time that chains of transmission are reported in Europe without known epidemiological links to West or Central Africa.” As perhaps obvious from the name, monkeypox was first found in monkeys and is spread through close contact, although it is not typically spread easily amongst humans.
The current outbreak (roughly 200 cases globally) extends to 20 countries in which monkeypox is not endemic, and is causing concern because the virus rarely spreads outside of West and Central Africa. Its symptoms include fever, headache, chills, exhaustion, asthenia, lymph node swelling, back pain and muscle aches.
Luckily, existing smallpox vaccinations are effective against monkeypox. Danish biotech company Bavarian Nordic is one of the few in the world to have approval for its smallpox vaccine, known as Imvanex in Europe and Jynneos in the United States. Iceland would receive a proportional allocation of the vaccine that the EU purchases for countries participating in the scheme, just like it did with the COVID-19 vaccine.